176 related articles for article (PubMed ID: 32681007)
1. Decreasing undesirable absorbed radiation to the intestine after administration of radium-223 dichloride for treatment of bone metastases.
Ogawa K; Higashi T; Mishiro K; Wakabayashi H; Shiba K; Odani A; Kinuya S
Sci Rep; 2020 Jul; 10(1):11917. PubMed ID: 32681007
[TBL] [Abstract][Full Text] [Related]
2. Complexes of myo-inositol-hexakisphosphate (InsP6) with zinc or lanthanum to enhance excretion of radioactive strontium from the body.
Ogawa K; Aoki M; Kadono S; Odani A
PLoS One; 2018; 13(4):e0195067. PubMed ID: 29614122
[TBL] [Abstract][Full Text] [Related]
3. [
Yang Y; Alencar LMR; Pijeira MSO; Batista BDS; França ARS; Rates ERD; Lima RC; Gemini-Piperni S; Santos-Oliveira R
Drug Deliv; 2022 Dec; 29(1):186-191. PubMed ID: 35191342
[TBL] [Abstract][Full Text] [Related]
4. Radium Ra 223 dichloride in castration-resistant prostate cancer.
Joung JY; Ha YS; Kim IY
Drugs Today (Barc); 2013 Aug; 49(8):483-90. PubMed ID: 23977665
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases.
Yoshida K; Kaneta T; Takano S; Sugiura M; Kawano T; Hino A; Yamamoto T; Shizukuishi K; Kaneko M; Zurth C; Inoue T
Ann Nucl Med; 2016 Aug; 30(7):453-60. PubMed ID: 27272279
[TBL] [Abstract][Full Text] [Related]
6. Use of Radium-223 Dichloride in Patients With Osteonecrosis of the Jaw Induced by Zoledronic Acid: Report of 2 Cases.
Dionisi V; Bellarosa C; Cardano R; Rizzini EL; Ghedini P; Morganti AG; Fanti S; Monari F
Clin Genitourin Cancer; 2019 Jun; 17(3):e612-e617. PubMed ID: 30956096
[No Abstract] [Full Text] [Related]
7. Dose estimation after a mixed field exposure: Radium-223 and intensity modulated radiotherapy.
Bastiani I; McMahon SJ; Turner P; Redmond KM; McGarry CK; Cole A; O'Sullivan JM; Prise KM; Ainsbury L; Anderson R
Nucl Med Biol; 2022; 106-107():10-20. PubMed ID: 34968973
[TBL] [Abstract][Full Text] [Related]
8. Radium-223 dichloride: a novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases.
McGann S; Horton ER
Ann Pharmacother; 2015 Apr; 49(4):469-76. PubMed ID: 25573268
[TBL] [Abstract][Full Text] [Related]
9. Micellar solution of [
Pijeira MSO; Gomes-da-Silva NC; Ricci-Junior E; Alencar LMR; İlem-Özdemir D; Cavalcanti ADS; Machado DE; Perini JA; Santos-Oliveira R
Int J Pharm; 2024 Mar; 652():123765. PubMed ID: 38195032
[TBL] [Abstract][Full Text] [Related]
10. The impact of age on radium-223 distribution and an evaluation of molecular imaging surrogates.
Jiang W; Ulmert D; Simons BW; Abou DS; Thorek DLJ
Nucl Med Biol; 2018; 62-63():1-8. PubMed ID: 29800797
[TBL] [Abstract][Full Text] [Related]
11. Excretion and whole-body retention of radium-223 dichloride administered for the treatment of bone metastases from castration resistant prostate cancer.
Pratt BE; Hindorf C; Chittenden SJ; Parker CC; Flux GD
Nucl Med Commun; 2018 Feb; 39(2):125-130. PubMed ID: 29189490
[TBL] [Abstract][Full Text] [Related]
12. Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why.
Gallicchio R; Mastrangelo PA; Nardelli A; Mainenti PP; Colasurdo AP; Landriscina M; Guglielmi G; Storto G
Tumori; 2019 Oct; 105(5):367-377. PubMed ID: 31096849
[TBL] [Abstract][Full Text] [Related]
13. Whole-Body and Microenvironmental Localization of Radium-223 in Naïve and Mouse Models of Prostate Cancer Metastasis.
Abou DS; Ulmert D; Doucet M; Hobbs RF; Riddle RC; Thorek DL
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26683407
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Single Photon Emission Computed Tomography of Alpha Particle-Emitting Radium-223.
Abou DS; Rittenbach A; Tomlinson RE; Finley PA; Tsui B; Simons BW; Jha AK; Ulmert D; Riddle RC; Thorek DLJ
Cancer Biother Radiopharm; 2020 Sep; 35(7):520-529. PubMed ID: 32182119
[No Abstract] [Full Text] [Related]
15. Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.
Uemura H; Uemura H; Nagamori S; Wakumoto Y; Kimura G; Kikukawa H; Yokomizo A; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Akagawa T; Matsubara N
Int J Clin Oncol; 2019 May; 24(5):557-566. PubMed ID: 30875000
[TBL] [Abstract][Full Text] [Related]
16. S-values for radium-223 and absorbed doses estimates for
Silva CCO; da Silva AX; Braz D; Lima LFC; Segars WP; de Sá LV
Appl Radiat Isot; 2022 Nov; 189():110387. PubMed ID: 36137481
[TBL] [Abstract][Full Text] [Related]
17. Radium-223 dichloride: a review of its use in patients with castration-resistant prostate cancer with symptomatic bone metastases.
Shirley M; McCormack PL
Drugs; 2014 Apr; 74(5):579-86. PubMed ID: 24610703
[TBL] [Abstract][Full Text] [Related]
18. The potential of
Murray I; Chittenden SJ; Denis-Bacelar AM; Hindorf C; Parker CC; Chua S; Flux GD
Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1832-1844. PubMed ID: 28612079
[TBL] [Abstract][Full Text] [Related]
19. Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting (223)Ra-dichloride.
Pacilio M; Ventroni G; De Vincentis G; Cassano B; Pellegrini R; Di Castro E; Frantellizzi V; Follacchio GA; Garkavaya T; Lorenzon L; Ialongo P; Pani R; Mango L
Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):21-33. PubMed ID: 26266887
[TBL] [Abstract][Full Text] [Related]
20. Safe Use of Radium-223 Dichloride (
Aro JL; Dinning SI; Leung EY; Zuckier LS
J Med Imaging Radiat Sci; 2019 Dec; 50(4S1):S36-S40. PubMed ID: 31383575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
